REEV, a medical technology startup specializing in intelligent wearable robotics, has raised $9.2 million to accelerate its efforts in improving mobility assistance for patients with gait disorders. The funding round was led by Newfund Heka, Polytechnique Ventures, and Irdi Capital, with additional backing from Techstars and a group of business angels, including French soccer player Raphaël Varane and knee surgeon Hervé Silbert, coordinated by Scala Patrimoine.
The company’s technology portfolio includes REEV SENSE, a motion sensor system that attaches to a patient’s shoe or leg for precise gait analysis, and DREEVEN, an electro-hydraulic wearable robotics system that provides personalized knee assistance. By focusing on reducing weight, lowering costs, and enhancing personalization, REEV aims to overcome key limitations of existing exoskeleton technologies. The first DREEVEN series is expected to launch in 2026.
REEV has achieved several milestones, including a clinical study at MIT’s Center for Clinical and Translational Research, funded by the Massachusetts eHealth Institute (MeHI). Additionally, the company has produced 100 commercial units of REEV SENSE, achieving both FDA and CE medical certifications, and has begun initial patient testing of DREEVEN functional units.
The new funding will be used to finalize DREEVEN’s design, support a clinical study at Boston University’s Neuromotor Recovery Lab under Dr. Lou Awad, and prepare for U.S. Food and Drug Administration (FDA) trials.
“With the support of our world-class partners, we are thrilled to enter the next phase of clinical and industrial development,” said Amaury Ciurana, REEV’s Co-Founder and CEO. Newfund Partner Anne-Sophie Saint-Martin added, “This funding marks a key milestone in improving mobility for neurological patients and advancing rehabilitation technologies.”
